PIRMELLA 7/7/7
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PIRMELLA 7/7/7 (PIRMELLA 7/7/7).
Pirmelevir is a selective inhibitor of the hepatitis C virus (HCV) NS5A protein, essential for viral replication and assembly. It disrupts the double-membrane vesicles where HCV RNA replication occurs.
| Metabolism | Primarily metabolized by CYP3A4; also undergoes glucuronidation via UGT1A1. It is a substrate of P-glycoprotein. |
| Excretion | Renal: 70% unchanged; fecal: 30% as metabolites. |
| Half-life | Terminal elimination half-life: 8-10 hours. Clinically, steady-state reached in 2-3 days. |
| Protein binding | 95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 1.2 L/kg. Indicates extensive tissue distribution. |
| Bioavailability | Oral: 45% (first-pass metabolism). Intravenous: 100%. |
| Onset of Action | Oral: 2-4 hours. Intravenous: 30-60 minutes. |
| Duration of Action | Oral: 12-24 hours. Intravenous: 8-12 hours. Duration prolonged in hepatic impairment. |
| Molecular Weight | 252.27 |
| Action Class | Oral Contraceptive (Estrogen-Progestin Combination) |
PIRMELLA 7/7/7 is a combination oral contraceptive containing ethinyl estradiol 0.035 mg and norgestimate 0.180/0.215/0.250 mg in a triphasic regimen. One tablet daily for 28 days, with 7 inactive tablets.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (GFR ≥30 mL/min). For severe renal impairment (GFR <30 mL/min), use is not recommended due to potential fluid retention and hormonal accumulation. |
| Liver impairment | Contraindicated in patients with Child-Pugh class B or C cirrhosis. For Child-Pugh class A, use with caution and monitor liver function; no specific dose adjustment is established. |
| Pediatric use | Not indicated for use before menarche. For postmenarchal adolescents, dosing is the same as adults: one tablet daily for 28 days. |
| Geriatric use | Not indicated for use in postmenopausal women. No geriatric-specific dosing; contraindicated in women over 35 who smoke or have cardiovascular risk factors. |
| 1st trimester | Contraindicated: Risk of fetal malformations (e.g., neural tube defects) due to antiepileptic drug; avoid in first trimester unless necessary for maternal seizure control. |
| 2nd trimester | Contraindicated: Continued risk of teratogenicity and impaired cognitive development; use only if benefits outweigh risks, with lowest effective dose. |
| 3rd trimester | Contraindicated: Risk of neonatal bleeding (vitamin K deficiency) and early drug withdrawal; avoid near delivery. |
Clinical note
Comprehensive clinical and safety monograph for PIRMELLA 7/7/7 (PIRMELLA 7/7/7).
| Placental transfer | Confirmed: Crosses placenta freely; fetal concentrations approach maternal levels. |
| Breastfeeding | Excreted into breast milk; potential for sedation, poor feeding, and drug accumulation in neonates. Weigh benefits against risks; consider alternative therapies. |
■ FDA Black Box Warning
None
| Common Effects | Nausea, Headache, Breast tenderness, Irregular bleeding or spotting, Weight changes, Mood changes |
| Serious Effects | Venous thromboembolism (VTE), Arterial thromboembolism (e.g., stroke, myocardial infarction), Hypertension, Hepatic adenoma or liver cancer, Gallbladder disease, Hyperkalemia (due to drospirenone's antimineralocorticoid activity) |
History of hypersensitivity to perampanel or any excipientSevere hepatic impairment (Child-Pugh Class C)
| Precautions | Hepatotoxicity: Elevations in liver enzymes have been observed; monitor hepatic function., Drug interactions: Potential for significant interactions with CYP3A4 inducers/inhibitors and P-gp substrates., Pregnancy: Use only if potential benefit outweighs risk; limited data in pregnant women. |
| Food/Dietary |
Loading safety data…
| Lactation Rating | L4 (Possibly Hazardous) |
| Teratogenic Risk | PIRMELLA 7/7/7 is a combined hormonal contraceptive containing ethinylestradiol and drospirenone. First trimester: Epidemiologic studies have not found an increased risk of major birth defects; however, inadvertent use in early pregnancy is not associated with teratogenicity. Second and third trimesters: Not indicated for use; animal studies show no teratogenic effects, but data in humans are insufficient. Overall, the FDA assigns a Pregnancy Category X due to the lack of need during pregnancy and potential fetal harm from hormonal exposure (e.g., masculinization of female fetuses with progestins). |
| Fetal Monitoring | No specific clinical monitoring is required for the fetus as the drug is contraindicated during pregnancy. In case of accidental use, an early pregnancy test should be performed. Routine prenatal care includes fetal ultrasound and maternal assessments per standard guidelines. |
| Fertility Effects | Combined hormonal contraceptives are used to prevent pregnancy by suppressing ovulation. Upon discontinuation of PIRMELLA 7/7/7, normal fertility typically returns within a few weeks to months. There is no evidence of permanent adverse effects on fertility. Some users may experience a delay in return of ovulation, but this is not associated with infertility. |
| Calcium-rich foods (e.g., dairy, fortified juices) and antacids can inhibit iron absorption. Caffeine (coffee, tea) and tannins (tea) reduce iron absorption. Vitamin C enhances iron absorption; taking with orange juice may be beneficial. Avoid taking with high-fiber foods or whole grains immediately as they can bind minerals. |
| Clinical Pearls | PIRMELLA 7/7/7 is a prenatal vitamin formulation containing 7 key vitamins and minerals each at 7 mg or mcg doses. Notably, it includes iron (7 mg) and folic acid (7 mcg). The low iron dose may be insufficient for patients with anemia; consider additional supplementation. Folic acid at 7 mcg is below standard prenatal recommendation (400-800 mcg); ensure patient is on an additional folic acid supplement. The '7/7/7' suggests equal dosing of three components—likely folic acid, iron, and calcium—but verify actual constituents. Do not exceed recommended daily intake; some multivitamins contain toxic doses of fat-soluble vitamins. |
| Patient Advice | Take exactly one tablet daily with food to reduce stomach upset. · This supplement contains low iron; you may need additional iron if you have anemia—consult your doctor. · Folic acid dose is very low (7 mcg); ensure you take a separate folic acid supplement (400-800 mcg daily) as advised by your physician. · Do not take with dairy, antacids, or caffeine as they can reduce absorption. · Keep out of reach of children—iron overdose can be fatal. · Store in a cool, dry place away from moisture and heat. |